Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
42 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
IBSA Pharma from Brussel, company number BE0795266574, closed financial year 2025 with a result of € 1,299 after tax. For that financial year IBSA Pharma recorded a gross margin of € 252,632 and equity of € 34,853. Compared with financial year 2024, the result moved from € 6,116 to € 1,299. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 19, 2026.
€ 34,853
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1,299
▼ 79% vs 2024
Profit after tax over the fiscal year.
€ 20,597
▼ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 9,853.
People and assets in 2025
2
Average over the fiscal year, from the social balance sheet.
€ 233,418
▼ 21% vs 2024
€ 116,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6,482
▼ 35% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 30,398
▼ 36% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 100,159 | € 317,984 | € 252,632 | ▼ 21% |
| Profit after taxes | € 2,438 | € 6,116 | € 1,299 | ▼ 79% |
| Equity | € 27,438 | € 33,554 | € 34,853 | ▲ 4% |
| Total debts | € 59,896 | € 57,245 | € 36,880 | ▼ 36% |
| Cash | € 15,259 | € 31,653 | € 20,597 | ▼ 35% |
| Retained profit | € 2,438 | € 8,554 | € 9,853 | ▲ 15% |
| Balance sheet total | € 87,334 | € 90,799 | € 71,733 | ▼ 21% |
| Employees (FTE) | - | 2 | 2 |
Key figures of IBSA Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IBSA Pharma?
What happened at IBSA Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1,299 (▼ 79% vs 2024). Source: NBB ↗
- Arturo-Pino Giuseppe Antonio LICENZIATI became a director. NBB
- Elisabetta Racca became a director. NBB
- New establishment in Brussel. KBO
- Luca Grassi became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 2,438 profit in 2023 to € 1,299 profit in 2025.
Paid € 22,741 in corporate taxes since 2023.
Best year ever: 2024, with € 6,116 profit.
On average € 126,300 of value added per employee in 2025.
A new publication or filing at IBSA Pharma? We notify you, reason included.
Follow IBSA PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind IBSA Pharma are Luca Grassi, Elisabetta Racca and Arturo-Pino Giuseppe Antonio LICENZIATI. The shares are held by IBSA HOLDING SA (100%).
Directors
According to the 2025 annual accounts
Luca Grassi
Director
since 2022
Elisabetta Racca
Director
since 2023
Arturo-Pino Giuseppe Antonio LICENZIATI
Director
since 2025
Shareholders
IBSA HOLDING SA
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
de Meeûssquare 37
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 42 companies are registered at this address.
All companies at this address →OUTOKUMPU
€ 790,627 gross margin · 2025
Hill and Knowlton International Belgium
€ 6.1 million revenue · 2025
Burson
€ 16.7 million revenue · 2025
European Business Aviation Association
€ -1.4 million gross margin · 2025
DOCTENA AFSPRAKEN
€ 14,492 gross margin · 2025
+37 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0795.266.574
- VAT number
- BE 0795.266.574
- Registered office
- de Meeûssquare 37, 1000 Brussel
- Names & denominations
- IBSA Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2022
- Peppol
- Active · Active since 26 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren